InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,113.20
(
0.65%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.24
(
-0.38%
)
Bitcoin
66,720.86
(
0.47%
)
Post# of 251581
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

floblu14

Send PM Follow Ignore
Followers 22
Posts 3630
Boards Moderated 0
Alias Born 07/20/2006

floblu14

Re: None

Monday, 09/28/2020 6:40:54 AM

Monday, September 28, 2020 6:40:54 AM

Post# of 251581
Revance price target raised to $35 from $32 at Barclays. RVNC Barclays analyst Balaji Prasad raised the firm's price target on Revance Therapeutics to $35 from $32 and keeps an Overweight rating on the shares after hosting an expert call with a physician treating neuromuscular injuries. If approved, Revance's DaxibotulinumtoxinA would be the only neurotoxin for plantar fasciitis use, Prasad tells investors in a research note.

Read more at:
https://thefly.com/n.php?id=3166413
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up